[Management of micro-inflammation in uremia].
Chronic micro-inflammation is commonly observed in patients with chronic renal failure. However, the causes of this micro-inflammation remain mainly indeterminated. Therefore, the appropriate therapeutic management of uremic microinflammation is not yet established. Meanwhile, it appears to be reasonable to use current non-specific anti-inflammatory therapies (e.g. ACEI, statins) in order to reduce uremic micro-inflammation. However, it is clear that such an approach is not sufficient, and further strategies (e.g. vitamin E) are warranted to optimize uremic micro-inflammation prevention.
Massy
Z A
ZA
Service de pharmacologie clinique, Service de néphrologie, Centre hospitalier universitaire, Amiens. massy@necker.fr
Choukroun
G
G
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000032:analysis; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007249:Inflammation / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000150:complications; D014511:Uremia / Q000150:complications*
D000806:Angiotensin-Converting Enzyme Inhibitors; D000975:Antioxidants; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002097:C-Reactive Protein